Taxifolin (Flavanonol) — Hermetica Encyclopedia
Named Bioactive Compounds · Compound

Taxifolin (Flavanonol)

Provisional Moderate Scoreflavonoid

Hermetica Superfood Encyclopedia

Evidence review status: unreviewed

Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.

Review flags: AWAITING_SEMANTIC_VALIDATION

Provisional Summary

Taxifolin is a flavanonol compound found in milk thistle and larch trees that functions as a potent antioxidant and anti-inflammatory agent. This bioactive flavonoid crosses the blood-brain barrier and may help reduce amyloid-beta protein accumulation associated with cognitive decline.

Screened PMID Records
Reported Benefits
Pending
Synergy Review
At a Glance
CategoryNamed Bioactive Compounds
GroupCompound
Public Score StatusProvisional Moderate
Primary Keywordtaxifolin benefits
Taxifolin close-up macro showing natural texture and detail — rich in antioxidant, anti-inflammatory, cardioprotective
Taxifolin (Flavanonol) — botanical close-up

Origin & History

Taxifolin growing in natural environment — natural habitat
Natural habitat

Taxifolin is a flavanonol, a subclass of flavonoids within the polyphenol family, naturally occurring in various plants including pine needles from Larix species, cedar, other conifers, as well as fruits like apples and grapes. Commercial extraction typically involves solvent extraction from plant sources such as larch wood or pine bark, followed by purification to isolate the compound.

No information on traditional or historical medicinal uses of taxifolin is available in the current research. The compound's therapeutic investigation appears to be a modern scientific endeavor.Traditional Medicine

Research Narrative (Provisional)

The primary human evidence comes from the ongoing T-COG trial (PMID: 41158654), a randomized, double-blind, placebo-controlled crossover study testing 100mg daily taxifolin in 60 patients with mild cognitive impairment or mild dementia over 12 weeks. One case report (n=1) documented improvements in a 42-year-old man with cerebral amyloid angiopathy, showing 22-24% reductions in brain amyloid deposition. No completed human RCTs or meta-analyses are available.

Preparation & Dosage

Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.

Nutritional Profile

Taxifolin (flavanonol/dihydroquercetin) is a pure bioactive flavonoid compound, not a whole food, so it contains no macronutrients (protein, fat, carbohydrates), fiber, or caloric value in isolated supplemental form. Molecular weight: 304.25 g/mol. Chemical formula: C15H12O7. Bioactive compound concentration in supplements typically ranges from 90-99% purity (standardized extracts, commonly sourced from Siberian larch bark, Larix sibirica). In larch bark raw material, taxifolin content ranges approximately 70-90 mg/g dry weight. In grape seeds and skin, taxifolin occurs at lower concentrations (~0.1-1 mg/g). As a flavanonol, it contains a 3-hydroxyflavanone skeleton with five hydroxyl groups, contributing to its antioxidant activity (ORAC value estimated >6,000 µmol TE/g in isolated form). Bioavailability is considered moderate-to-low due to limited aqueous solubility (~0.5 mg/mL at room temperature); absorption occurs primarily in the small intestine with some colonic microbial metabolism producing phenolic acid metabolites (phloroglucinol, 3,4-dihydroxyphenylacetic acid). Lipid-based or nanoparticle formulations improve bioavailability by an estimated 2-4 fold. No significant vitamin or mineral content is inherent to the isolated compound.

Reported Mechanism (Provisional)

Mechanism of Action

Taxifolin exerts its effects through multiple antioxidant pathways, including scavenging reactive oxygen species and chelating metal ions that promote oxidative stress. The compound modulates inflammatory mediators like NF-κB and cyclooxygenase enzymes while supporting mitochondrial function. In brain tissue, taxifolin may interfere with amyloid-beta protein aggregation and promote clearance of these neurotoxic plaques.

Clinical Narrative (Provisional)

Clinical evidence for taxifolin remains limited and preliminary. The ongoing T-COG trial (n=60) is investigating taxifolin's effects on cognitive function in mild cognitive impairment using Montreal Cognitive Assessment scores, but results are not yet available. One case report suggested a 22-24% reduction in brain amyloid-beta deposition, though single case studies provide weak evidence. Most research consists of preclinical studies in cell cultures and animal models rather than human trials.

Also Known As

Dihydroquercetin3,3',4',5,7-pentahydroxyflavanoneDHQTaxifoliolDistylin3,5,7,3',4'-pentahydroxyflavanone

Explore the Full Encyclopedia

Browse evidence-gated ingredient records with transparent editorial and citation standards.

Browse Ingredients
These statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
From the Hermetica Research Desk

Research updates — and 25% off your first order

Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.

Educational content only — not medical advice.